Abstract
BackgroundTherapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have